U-25/12/159-164/Amend-Price/2025-MedV(E:1222663)　　　　Dt.:23-12-2025　　सेवा १

Director (Medical) Delhi/Director (Medical) NOIDA
Dean, All ESIC PGIMSR's, Medical & Dental Colleges
Medical Superintendents-All ESIC Hospitals
Director, ESI Scheme-All States

संशोधन/Amendment - 17/2025
Sub: Downward Rate Revision of Items under DGESIC RC-161 -reg.

Ref: U-25/12/RC/159to163/2022-Med.V(E-117064), valid w.e.f. 08.04.2025 to 07.04.2027

Sir/Madam,

　　　　The following amendment may please be noted in r/o Item no. 600 in RC 161 of
M/s Johnson & Johnson Private Ltd.:

RC No ItemNo	Item Name and Description	Initial / Existing Rate in DGESIC RC	**Amendment Revised Rate**	Difference in rates to be deducted for supply orders placed wef
161 600	Infliximab Inj. Each Vial to contain: Infliximab 100mg (REMICADE) Packing:1 Vial	Initial Rate= Rs.14,158.11 per Vial After revision, Existing Rate=Rs.13,500.00 per Vial	**Rs.11,982.00 per Vial**	15th Oct. 2025

GST @5% Extra

1. The said amendment has been issued on the request of the firms-**M/s Johnson & Johnson Private Ltd.**
2. The drug shall adhere to composition, strength, standards and packing as approved under the Rate Contract & conform to the standards and specifications as per Drug & Cosmetic Act.
3. All DDOs are advised to recover the excess amount paid to the firm from subsequent bills submitted by the firm and maintain records of the same.
4. Reconciliation / recovery under the said amendment is the sole responsibility of the Competent Authority / DDOs of the respective institution.

यह पत्र महानिदेशक, क.रा.बी.निगम के अनुमोदन से जारी किया जाता है।

Digitally signed by
Sanjiv Kochhar
Date: 24-12-2025
उप)(चिकित्सा)5 आयुक्त

Copy for information to:

1. M/s Johnson & Johnson Private Ltd. (**rasawale@its.jnj.com**)

2. Website Content Manager with request for uploading on ESIC website.
3. Guard file / Spare copy